Switch to:
Also traded in: Israel

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 150.56
KMDA's Cash to Debt is ranked higher than
54% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. KMDA: 150.56 )
Ranked among companies with meaningful Cash to Debt only.
KMDA' s Cash to Debt Range Over the Past 10 Years
Min: 1.32  Med: 5.03 Max: N/A
Current: 150.56
Equity to Asset 0.71
KMDA's Equity to Asset is ranked higher than
53% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. KMDA: 0.71 )
Ranked among companies with meaningful Equity to Asset only.
KMDA' s Equity to Asset Range Over the Past 10 Years
Min: 0.28  Med: 0.62 Max: 0.69
Current: 0.71
0.28
0.69
F-Score: 4
Z-Score: 1.72
M-Score: -2.70
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -16.29
KMDA's Operating margin (%) is ranked higher than
62% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. KMDA: -16.29 )
Ranked among companies with meaningful Operating margin (%) only.
KMDA' s Operating margin (%) Range Over the Past 10 Years
Min: -121.42  Med: -16.15 Max: 5.83
Current: -16.29
-121.42
5.83
Net-margin (%) -16.07
KMDA's Net-margin (%) is ranked higher than
62% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. KMDA: -16.07 )
Ranked among companies with meaningful Net-margin (%) only.
KMDA' s Net-margin (%) Range Over the Past 10 Years
Min: -170.4  Med: -18.59 Max: 0.63
Current: -16.07
-170.4
0.63
ROE (%) -15.02
KMDA's ROE (%) is ranked higher than
62% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. KMDA: -15.02 )
Ranked among companies with meaningful ROE (%) only.
KMDA' s ROE (%) Range Over the Past 10 Years
Min: -196.96  Med: -20.08 Max: 1.83
Current: -15.02
-196.96
1.83
ROA (%) -10.23
KMDA's ROA (%) is ranked higher than
66% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. KMDA: -10.23 )
Ranked among companies with meaningful ROA (%) only.
KMDA' s ROA (%) Range Over the Past 10 Years
Min: -59.2  Med: -11.02 Max: 0.58
Current: -10.23
-59.2
0.58
ROC (Joel Greenblatt) (%) -22.94
KMDA's ROC (Joel Greenblatt) (%) is ranked higher than
69% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. KMDA: -22.94 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
KMDA' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -111.83  Med: -13.64 Max: 26.43
Current: -22.94
-111.83
26.43
Revenue Growth (3Y)(%) -2.70
KMDA's Revenue Growth (3Y)(%) is ranked lower than
55% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. KMDA: -2.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
KMDA' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -2.7  Med: 24.60 Max: 44.1
Current: -2.7
-2.7
44.1
» KMDA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

KMDA Guru Trades in Q4 2014

Jim Simons 123,406 sh (+82.18%)
John Paulson 739,356 sh (-1.42%)
» More
Q1 2015

KMDA Guru Trades in Q1 2015

Jim Simons 169,100 sh (+37.03%)
John Paulson 739,356 sh (unchged)
» More
Q2 2015

KMDA Guru Trades in Q2 2015

Jim Simons 204,400 sh (+20.88%)
John Paulson 739,356 sh (unchged)
» More
Q3 2015

KMDA Guru Trades in Q3 2015

John Paulson 739,356 sh (unchged)
Jim Simons 156,500 sh (-23.43%)
» More
» Details

Insider Trades

Latest Guru Trades with KMDA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 26.88
KMDA's Forward P/E is ranked lower than
78% of the 344 Companies
in the Global Biotechnology industry.

( Industry Median: 16.75 vs. KMDA: 26.88 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 1.84
KMDA's P/B is ranked higher than
66% of the 1123 Companies
in the Global Biotechnology industry.

( Industry Median: 2.60 vs. KMDA: 1.84 )
Ranked among companies with meaningful P/B only.
KMDA' s P/B Range Over the Past 10 Years
Min: 1.41  Med: 3.12 Max: 11.31
Current: 1.84
1.41
11.31
P/S 1.97
KMDA's P/S is ranked higher than
89% of the 1126 Companies
in the Global Biotechnology industry.

( Industry Median: 8.95 vs. KMDA: 1.97 )
Ranked among companies with meaningful P/S only.
KMDA' s P/S Range Over the Past 10 Years
Min: 1.57  Med: 3.88 Max: 13.13
Current: 1.97
1.57
13.13
Current Ratio 2.88
KMDA's Current Ratio is ranked lower than
64% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. KMDA: 2.88 )
Ranked among companies with meaningful Current Ratio only.
KMDA' s Current Ratio Range Over the Past 10 Years
Min: 2.21  Med: 3.19 Max: 4.42
Current: 2.88
2.21
4.42
Quick Ratio 1.99
KMDA's Quick Ratio is ranked lower than
70% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. KMDA: 1.99 )
Ranked among companies with meaningful Quick Ratio only.
KMDA' s Quick Ratio Range Over the Past 10 Years
Min: 1.45  Med: 2.32 Max: 3.59
Current: 1.99
1.45
3.59
Days Inventory 176.46
KMDA's Days Inventory is ranked lower than
65% of the 416 Companies
in the Global Biotechnology industry.

( Industry Median: 126.53 vs. KMDA: 176.46 )
Ranked among companies with meaningful Days Inventory only.
KMDA' s Days Inventory Range Over the Past 10 Years
Min: 34.72  Med: 125.92 Max: 187.18
Current: 176.46
34.72
187.18
Days Sales Outstanding 135.10
KMDA's Days Sales Outstanding is ranked lower than
81% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. KMDA: 135.10 )
Ranked among companies with meaningful Days Sales Outstanding only.
KMDA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 69.61  Med: 89.95 Max: 97.76
Current: 135.1
69.61
97.76
Days Payable 141.53
KMDA's Days Payable is ranked higher than
77% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 57.67 vs. KMDA: 141.53 )
Ranked among companies with meaningful Days Payable only.
KMDA' s Days Payable Range Over the Past 10 Years
Min: 89.24  Med: 116.34 Max: 138.19
Current: 141.53
89.24
138.19

Valuation & Return

vs
industry
vs
history
Price/Net Cash 9.24
KMDA's Price/Net Cash is ranked lower than
62% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: 18.00 vs. KMDA: 9.24 )
Ranked among companies with meaningful Price/Net Cash only.
KMDA' s Price/Net Cash Range Over the Past 10 Years
Min: 9.82  Med: 15.31 Max: 25.84
Current: 9.24
9.82
25.84
Price/Net Current Asset Value 2.51
KMDA's Price/Net Current Asset Value is ranked higher than
75% of the 898 Companies
in the Global Biotechnology industry.

( Industry Median: 5.24 vs. KMDA: 2.51 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
KMDA' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.21  Med: 6.07 Max: 38.13
Current: 2.51
2.21
38.13
Price/Tangible Book 1.80
KMDA's Price/Tangible Book is ranked higher than
79% of the 1051 Companies
in the Global Biotechnology industry.

( Industry Median: 3.98 vs. KMDA: 1.80 )
Ranked among companies with meaningful Price/Tangible Book only.
KMDA' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.61  Med: 4.55 Max: 9.99
Current: 1.8
1.61
9.99
Price/Median PS Value 0.58
KMDA's Price/Median PS Value is ranked higher than
75% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. KMDA: 0.58 )
Ranked among companies with meaningful Price/Median PS Value only.
KMDA' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.46  Med: 1.02 Max: 3.38
Current: 0.58
0.46
3.38
Earnings Yield (Greenblatt) (%) -10.57
KMDA's Earnings Yield (Greenblatt) (%) is ranked lower than
56% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. KMDA: -10.57 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
KMDA' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -10.57  Med: 1.00 Max: 2.7
Current: -10.57
-10.57
2.7

More Statistics

Revenue(Mil) $70
EPS $ -0.31
Beta1.06
Short Percentage of Float0.03%
52-Week Range $3.09 - 5.15
Shares Outstanding(Mil)35.99

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 337 394 426
EPS($) -0.19 -0.19 1.98
EPS without NRI($) -0.19 -0.19 1.98

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:KMDA.Israel,
Kamada Ltd. develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company's product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises of Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases and Heparin Lock Flush to maintain potency of intravenous injection device among other. Its business is segmented into two - Proprietary Product and Distribution. The Proprietary Product segment develops and manufactures plasma-derived therapeutics and market them in more than 15 countries. The Distribution segment distributes drugs manufactured by third-parties for critical use in Israel, produced from plasma or its derivative products.
» More Articles for KMDA

Headlines

Articles On GuruFocus.com
Weekly 3-Year Low Highlights: FMS, SNOW, KMDA, LAYN Jun 16 2014 

More From Other Websites
Kamada Ltd. Earnings Analysis: 2015 By the Numbers Feb 05 2016
Kamada to Present at Source Capital Group’s 2016 Disruptive Growth & Healthcare Conference Feb 05 2016
New Strong Buy Stocks for February 4th Feb 04 2016
Kamada posts 4Q profit Feb 02 2016
Kamada posts 4Q profit Feb 02 2016
Kamada Reports 2015 Fourth Quarter and Full Year Financial Results Feb 02 2016
Kamada to Host Fourth Quarter and Year End 2015 Financial Results Conference Call on February 2,... Jan 27 2016
Kamada Reports Further Positive Interim Data from Phase 1/2 Study of its Alpha-1 Antitrypsin to... Jan 06 2016
Kamada Reports Further Positive Interim Data from Phase 1/2 Study of its Alpha-1 Antitrypsin to... Jan 06 2016
Kamada (KMDA) Reports Encouraging Data on Rabies Drug Dec 29 2015
Kamada Ltd. Earnings Analysis: Q3, 2015 By the Numbers Dec 23 2015
New Strong Sell Stocks for December 23rd Dec 23 2015
Kamada’s Human Rabies Immune Globulin Successfully Meets Primary Endpoint in U.S. Pivotal Phase... Dec 23 2015
Kamada's rabies drug succeeds in trial Dec 23 2015
Kamada’s Human Rabies Immune Globulin Successfully Meets Primary Endpoint in U.S. Pivotal Phase... Dec 23 2015
Evogene Appoints Eyal Leibovitz as Chief Financial Officer Dec 22 2015
Kamada Provides Update on Alpha-1 Antitrypsin Development in Newly Diagnosed Type 1 Diabetes Dec 09 2015
Kamada Completes Enrollment of U.S. Phase 2 Study of Inhaled Alpha-1 Antitrypsin for the Treatment... Dec 09 2015
KAMADA LTD Financials Dec 08 2015
Kamada Completes Enrollment of U.S. Phase 2 Study of Inhaled Alpha-1 Antitrypsin for the Treatment... Dec 08 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK